Beck Bode LLC acquired a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND – Free Report) in the 4th quarter, Holdings Channel.com reports. The firm acquired 81,087 shares of the biotechnology company’s stock, valued at approximately $17,291,000. Ascendis Pharma A/S accounts for 2.9% of Beck Bode LLC’s portfolio, making the stock its 15th biggest holding.
Several other institutional investors and hedge funds have also bought and sold shares of the company. Legato Capital Management LLC lifted its position in Ascendis Pharma A/S by 15.8% during the fourth quarter. Legato Capital Management LLC now owns 2,023 shares of the biotechnology company’s stock worth $431,000 after purchasing an additional 276 shares during the period. Global Retirement Partners LLC lifted its position in Ascendis Pharma A/S by 111.9% during the fourth quarter. Global Retirement Partners LLC now owns 214 shares of the biotechnology company’s stock worth $46,000 after purchasing an additional 113 shares during the period. Leonteq Securities AG bought a new stake in Ascendis Pharma A/S during the fourth quarter worth about $36,000. PSP Research LLC bought a new stake in Ascendis Pharma A/S during the fourth quarter worth about $550,000. Finally, Fideuram Intesa Sanpaolo Private Banking S.P.A. bought a new stake in Ascendis Pharma A/S during the fourth quarter worth about $2,317,000.
Ascendis Pharma A/S Stock Down 0.2%
Shares of NASDAQ ASND opened at $247.05 on Friday. The company has a current ratio of 1.00, a quick ratio of 0.72 and a debt-to-equity ratio of 0.79. The company has a market cap of $15.41 billion, a price-to-earnings ratio of 28.49 and a beta of 0.41. Ascendis Pharma A/S has a 12 month low of $153.49 and a 12 month high of $250.74. The stock has a 50-day moving average price of $232.68 and a two-hundred day moving average price of $221.82.
Wall Street Analyst Weigh In
Several equities research analysts recently weighed in on the stock. Wolfe Research reaffirmed an “outperform” rating and set a $260.00 price objective on shares of Ascendis Pharma A/S in a research report on Monday, March 2nd. Evercore reaffirmed an “outperform” rating and set a $329.00 price objective on shares of Ascendis Pharma A/S in a research report on Friday, May 15th. Oppenheimer upped their price objective on shares of Ascendis Pharma A/S from $246.00 to $262.00 and gave the stock an “outperform” rating in a research report on Thursday, February 12th. Stifel Nicolaus set a $332.00 price objective on shares of Ascendis Pharma A/S in a research report on Wednesday, March 4th. Finally, Wells Fargo & Company cut their price objective on shares of Ascendis Pharma A/S from $330.00 to $326.00 and set an “overweight” rating for the company in a research report on Friday, May 8th. Two analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $295.39.
Get Our Latest Stock Report on Ascendis Pharma A/S
Insider Buying and Selling
In other Ascendis Pharma A/S news, insider Flemming Steen Jensen sold 19,460 shares of the business’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $238.49, for a total transaction of $4,641,015.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 40.00% of the company’s stock.
Ascendis Pharma A/S Profile
Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.
The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.
Featured Stories
- Five stocks we like better than Ascendis Pharma A/S
- Workday Validates AI Flywheel: Stock Price Recovery Begins
- HubSpot at 2019 Levels Is an Opportunity—Not a Warning
- Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus?
- Kiniksa Pharmaceuticals Still Has Room to Run After 100% Rally
Want to see what other hedge funds are holding ASND? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ascendis Pharma A/S (NASDAQ:ASND – Free Report).
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.
